We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Trial watch: Atopic dermatitis therapy breakthrough on the horizon?
- Authors
Cully, Megan
- Abstract
The article reports on two studies which suggest that dupilumab, a monoclonal antibody, has the potential therapeutic use for atopic dermatitis and asthma. It states that dupilumab is being developed by pharmaceutical firms Regeneron Pharmaceuticals Inc. and Sanofi-Aventis SA and to be approved by the U.S. Food & Drug Administration (FDA). Insights from Lisa Beck, professor at the Department of Dermatology in the University of Rochester Medical Center, are presented.
- Subjects
THERAPEUTIC use of monoclonal antibodies; ATOPIC dermatitis treatment; ASTHMA treatment; REGENERON Pharmaceuticals Inc.; SANOFI-Aventis SA; UNITED States. Food &; Drug Administration; BECK, Lisa; UNIVERSITY of Rochester (Rochester, N.Y.). Medical Center
- Publication
Nature Reviews Drug Discovery, 2014, Vol 13, Issue 9, p645
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd4414